Effects of psychoactive substances in schizophrenia - findings of structural and functional neuroimaging

Current Topics in Medicinal Chemistry

Volumn 12, Issue 21, 2012, Pages 2426-2433

  Walter, M ^a   Denier, N ^a   Vogel, M ^a   Lang, U E ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Alcohol; Drug; Functional magnetic resonance imaging; Schizophrenia; Structural magnetic resonance imaging; Substance use disorders

Indexed keywords

ALCOHOL; AMPHETAMINE; CANNABIS; COCAINE; DIAMORPHINE; HYDROCORTISONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NICOTINIC RECEPTOR; PSYCHOTROPIC AGENT; SEROTONIN RECEPTOR;

AGGRESSION; BLOOD PRESSURE; BRAIN BLOOD FLOW; BRAIN SIZE; COGNITION; COMORBIDITY; DRUG ABUSE; DRUG USE; ELECTROENCEPHALOGRAPHY; EUPHORIA; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; IRRITABILITY; PREVALENCE; PSYCHOSIS; PULSE RATE; REVIEW; RISK FACTOR; SCHIZOPHRENIA;

EID: 84874853045     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612805289971     Document Type: Review

References (107)

1. Liddle, P.F. The symptoms of chronic schizophrenia: A re- examination of the positive-negative dichotomy. Br J Psychiatr, 1987, 151, 145-151.
2. Mueser, K.T., McGurk, S.R. Schizophrenia. Lancet, 2004, 363, 2063-2072.
3. Lawrie, S.M.; Abukmeil, S.S. Brain abnormality in schizophrenia: a systematic and quantitative review of volumetric magnetic resonance imaging. Br J Psychiatry, 1998, 172, 110-120.
4. Wright, I.C.; Rabe-Hesketh, S.; Woodruff, P.W.; David, A.S.; Murray, R.M.; Bullmore, E.T. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry, 2000, 157, 16-25.
5. Borgwardt, S.J.; Riecher-Rossler, A.; Dazzan, P.; Chitnis, X.; Aston, J.; Drewe, M.; Gschwandtner, U.; Haller, S.; Pfluger, M.; Rechsteiner, E.; D'Souza, M.; Stieglitz, R.D.; Radu, E.W.; McGuire, P.K. Regional gray matter volume abnormalities in the at risk mental state. Biol Psychiatry, 2007, 61, 1148-1156.
6. Borgwardt, S.J.; Picchioni, M.M.; Ettinger, U.; Toulopoulou, T.; Murray, R.; McGuire, P.K. Regional gray matter volume in monozygotic twins concordant and discordant for schizophrenia. Biol Psychiatry, 2010, 67, 956-964.
7. Leshner, A.I. Addiction is a brain disease, and it matters. Science, 1997, 278, 45-47.
8. McKay, J.R.; Alterman, A.I.; Mulvaney, F.D.; Koppenhaver, J.M. Predicting proximal factors in cocaine relapse and near miss episodes: clinical and theoretical implications. Drug Alcohol Depend, 1999, 56, 67-78.
9. Sinha, R.; Garcia, M.; Paliwal, P.; Kreek, M.J.; Rounsaville, B.J. Stress-induced cocaine craving and hypothalamic-pituitary-adrenal responses are predictive of cocaine relapse outcome. Arch Gen Psychiatry 2006, 63, 324-331.
10. Volkow, N.D.; Wang, G.J.; Fowler, J.S.; Tomasi, D., Telang, F. Addiction: beyond dopamine reward circuitry. Proc Natl Acad Sci U S A, 2011, 108, 15037-15042.
11. Heinz, A.; Siessmeier, T.; Wrase, J.; Hermann, D.; Klein, S.; Grüsser, S.M.; Flor, H.; Braus, D.F.; Buchholz, H.G.; Gründer, G.; Schreckenberger, M.; Smolka, M.N.; Rösch, F.; Mann, K., Barten- stein, P. Correlation between dopamine D2 receptors in the ventral striatum and central processing of alcohol cues and craving. Am J Psychiatry, 2004, 161, 1783-1789.
12. Hyman, S.E.; Malenka, R.C.; Nestler, E.J. Neural mechanisms of addiction: the role of reward-related learning and memory. Annu Rev Neurosci, 2006, 29, 565-598.
13. Kessler, R.C.; Berglund, P.; Demler, O.; Jin, R.; Merikangas, K.R.; Walters, E.E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry, 2005, 62, 593-602.
14. McBride, O.; Teesson, M.; Slade, T.; Hasin, D.; Degenhardt, L.; Baillie, A. Further evidence of differences in substance use and dependence between Australia and the United States. Drug Alcohol Depend, 2009, 100: 258-264.
15. Regier, D.A.; Farmer, M.E.; Rae, D.S.; Locke, B.Z.; Keith, S.J.; Judd, L.L.; Goodwin, F.K. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA, 1990, 264, 2511-2508.
16. Chambers, R.A.; Krystal, J.H.; Self, D.W. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry, 2001, 50, 71-83.
17. Duke, P.J.; Pantelis, C.; McPhillips, M.A.; Barnes, T.R.E. Comorbid non-alcohol substance misuse among people with schizophrenia. Br J Psychiatry, 2001, 179: 509-513.
18. J. Psychopharmacological boundaries of schizophrenia with comorbid cannabis use disorder: a critical review. Curr Pharm Des, 2012 Jun 6. [Epub ahead of print]
19. Ashburner, J.; Friston, K.J. Voxel-based morphometry-the meth- ods. Neuroimage, 2000, 11, 805-821.
20. Logothetis, N.K. What we can do and what we cannot do with fMRI. Nature, 2008, 453: 869-878.
21. Ogawa, S.; Lee, T.M.; Kay, A.R.; Tank, D.W. Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc Natl Acad Sci USA, 1990, 87, 9868-9872.
22. Fox, M.D.; Raichle, M.E. Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. Nat Rev Neurosci, 2007; 8, 700-711.
23. Cami, J.; Farre, M. Drug addiction. N Engl J Med 2003, 349, 975-986.
24. Spanagel, R.; Montkowski, A.; Allingham, K; Stohr, T.; Shoaib, M.; Holsboer, F.; Landgraf, R. Anxiety: a potential predictor of vulnerability to the initiation of enthanol self-administration in rats. Psychopharmacology, 1995, 122, 369-373.
25. Holdstock, L.; de Wit, H. Individual differences in the biphasic effects of ethanol. Alcohol Res Exp Res, 1998, 22, 1903-1911.
26. Koob, G.F.; Le Moal, M. Neurobiology of Addiction. Elsevier: London, 2006.
27. Kosel, M.; Noss, R.S.; Hämmig, R.; Wielepp, P.; Bundeli, P.; Heidbreder, R.; Kinser, J.A.; Brenneisen, R.; Fisch, H.U.; Kayser, S.; Schlaepfer, T.E. Cerebral blood flow effects of acute intrave- nous heroin administration. Eur Neuropsychopharmacol, 2008, 18, 278-285.
28. Walter, M.; Wiesbeck, G.A.; Bloch, N.; Aeschbach, S.; Olbrich, H.M., Seifritz, E.; Dürsteler-MacFarland, K.M. Psychobiological responses to drug cues before and after methadone intake in heroin-dependent patients: a pilot study. Eur Neuropsychopharmacol, 2008, 18, 390-393.
29. Walter, M.; Wiesbeck, G.A.; Degen, B.; Albrich, J.; Schulz, A.; Schächinger, H.; Dürsteler-MacFarland, K.M. Heroin reduces startle and cortisol response in opioid-maintained heroin-dependent patients. Addict Biol, 2011, 16, 145-151.
30. Koob, G.F., Le Moal, M. Drug abuse: hedonic homeostatic dys- regulation. Science, 1997, 278, 52-58.
31. Swann, A.C.; Bjork, J.M.; Moeller, F.G.; Dougherty, D.M. Two models of impulsivity: relationship to personality traits and psychopathology. Biol Psychiatr, 2002, 51, 988-994.
32. Scott, J.C.; Woods, S.P.; Matt, G.E.; Meyer, R.A.; Heaton, R.K.; Atkinson, J.H.; Grant, I. Neurocognitive effects of methampheta- mine: a critical review and meta-analysis. Neuropsychol Rev, 2007, 17, 275-297.
33. Hirst, R.A.; Lambert, D.G.; Notcutt, W.G. Pharmacology and potential therapeutic uses of cannabis. Br J Anaesth, 1998, 81, 77-84.
34. Williamson, E.M.; Evans, FJ. Cannabinoids in clinical practice. Drugs, 2000, 60, 1303-1014.
35. Johnson, BA. Psychopharmacological effects of cannabis. Br J Hosp Med, 1990, 43, 114-116.
36. Gonzalez, R. Acute and non-acute effects of cannabis on brain functioning and neuropsychological performance. Neuropsychol Rev, 2007, 17, 347-361.
37. DeLisi, L.E. The effect of cannabis on the brain: can it cause brain anomalies that lead to increased risk for schizophrenia? Curr Opin Psychiatry, 2008, 21, 140-150.
38. Schneider, M. Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure. Addict Biol, 2008, 13, 253-263.
39. D'Souza, D.C.; Perry, E.; MacDougall, L.; Ammerman, Y.; Cooper, T.; Wu, Y.T.; Braley, G.; Gueorguieva, R.; Krystal, J.H. The psychotomimetic effects of intravenousdelta-9- tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology, 2004, 29, 1558-1572.
40. Bhattacharyya, S.; Crippa, J.A.; Allen, P.; Martin-Santos, R.; Borgwardt, S.; Fusar-Poli, P.; Rubia, K; Kambeitz, J.; O'Carroll, C; Seal, M.L.; Giampietro, V.; Brammer, M.; Zuardi, A.W.; Atakan, Z.; McGuire, P.K. Induction of psychosis by A9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Arch Gen Psychiatry, 2012, 69, 27-36.
41. Bhattacharyya, S.; Atakan, Z.; Martin-Santos, R.; Crippa, J.A.; McGuire, P.K. Neural Mechanisms for the Cannabinoid Modulation of Cognition and Affect in Man: a Critical Review of Neuroimaging Studies. Curr Pharm Des, 2012, Jun 6. [Epub ahead of print]
42. Barnes, T.R.; Mutsatsa, S.H.; Hutton, S.B.; Watt, H.C.; Joyce, E.M. Comorbid substance abuse and age of onset of schizophrenia. Br J Psychiatry, 2006, 188, 237-242.
43. Van der Meer, F.J.; Velthorst, E.; Meijer, C.J.; Machielsen, M.W.; de Haan, L. Cannabis use in patients at clinical high risk of psy- chosis: Impact on prodromal symptoms and transition to psychosis. Curr Pharm Des, 2012, Jun 7. [Epub ahead of print]
44. Bühler, M.; Mann, K. Alcohol and the human brain: A systematic review of different neuroimaging methods. Alcohol Clin Exp Res, 2011, 35, 1771-1793.
45. Makris, N.; Oscar-Berman, M.; Kim, S.; Hodge, S.M.; Kennedy, D.N.; Caviness, V.S.; Phil, D.; Marinkovic, K.; Breiter, H.C.; Gasic, G.P.; Harris, G.J. Decreased volume of the brain reward system in alcoholism. Biol Psychiatry, 2008, 64, 192-202.
46. Pfefferbaum, A.; Sullivan, E.V.; Mathalon, D.H.; Lim, K.O. Frontal lobe volume loss observed with magnetic resonance imaging in older chronic alcoholics. Alcohol Clin Exp Res, 1997, 21, 521-529.
47. Gilman, J.M.; Ramchandani, V.A.; Davis, M.B.; Bjork, J.M.; Hommer, D.W. Why we like to drink: a functional magnetic resonance imaging study of the rewarding and anxiolytic effects of alcohol. J Neurosci, 2008, 28, 4583-4591.
48. Sripada, C.S.; Angstadt, M.; McNamara, P.; King, A.C.; Phan, K.L. Effects of alcohol on brain responses to social signals of threat in humans. Neuroimage, 2011, 55, 371-380.
49. Lyoo, I.K.; Pollack, M.H.; Silveri, M.M.; Ahn, K.H.; Diaz, C.I.; Hwang, J.; Kim, S.J.; Yurgelun-Todd, D.A.; Kaufman, M.J.; Renshaw, P.F. Prefrontal and temporal gray matter density decreases in opiate dependence. Psychopharmacology (Berl), 2006, 184, 139-144.
50. Upadhyay, J.; Maleki, N.; Potter, J.; Elman, I.; Rudrauf, D.; Knud- sen, J.; Wallin, D.; Pendse, G.; McDonald, L.; Griffin, M.; Anderson, J.; Nutile, L.; Renshaw, P.; Weiss, R.; Becerra, L.; Borsook, D. Alterations in brain structure and functional connectivity in prescription opioid-dependent patients. Brain, 2010, 133, 2098-2114.
51. Yuan, K.; Qin, W.; Dong, M.; Liu, J.; Sun, J.; Liu, P.; Zhang, Y.; Wang, W.; Wang, Y.; Li, Q.; Zhao, L.; von Deneen, K.M.; Liu, Y.; Gold, M.S.; Tian, J. Yuan K, Qin W, Dong M, Liu J, Sun J, Liu P, et al. Gray matter deficits and resting-state abnormalities in abstinent heroin-dependent individuals. Neurosci Lett, 2010, 482, 101-105.
52. Yuan, Y., Zhu, Z.; Shi, J.; Zou, Z.; Yuan, F.; Liu, Y.; Lee, T.M.; Weng, X. Gray matter density negatively correlates with duration of heroin use in young lifetime heroin-dependent individuals. Brain Cog, 2009, 71, 223-228.
53. Forman, S.D.; Dougherty, G.G.; Casey, B.J.; Siegle, G.J.; Braver, T.S.; Barch, D.M.; Stenger, V.A.; Wick-Hull, C.; Pisarov, L.A.; Lorensen, E. Opiate addicts lack error-dependent activation of rostral anterior cingulate. Biol Psychiatry, 2004, 55, 531-537.
54. Lee, T.M.C.; Zhou, W.H.; Luo, X.J.; Yuen, K.S.L.; Ruan, X.Z.; Weng, X.C. Neural activity associated with cognitive regulation in heroin users: A fMRI study. Neurosci Lett, 2005, 382, 211-216.
55. Fu, L.P.; Bi, G.H.; Zou, Z.T.; Wang, Y.; Ye, E.M.; Ma, L.; Ming- Fan; Yang, Z. Impaired response inhibition function in abstinent heroin dependence. Neurosci Lett, 2008, 27, 322-326.
56. Xiao, Z.; Lee, T.; Zhang, J.X.; Wu, Q.; Weng, X. Thirsty heroin addicts show different fMRI activations when exposed to water-related and drug-related cues. Drug Alcohol Depend, 2006, 83, 157-162.
57. Yang, Z.; Xie, J.; Shao, Y.C.; Xie, C.M.; Fu, L.P.; Li, D.J.; Fan, M.; Ma, L.; Li, S.J. Dynamic neural responses to cue-reactivity paradigms in heroin-dependent users: an fMRI study. Hum Brain Mapp, 2009, 30, 766-775.
58. Langleben, D.D.; Ruparel, K.; Elman, I.; Busch-Winokur, S.; Pratiwadi, R.; Loughead, J.; O'Brien, C.P.; Childress, A.R. Acute effect of methadone maintenance dose on brain FMRI response to heroin-related cues. Am J Psychiatry, 2008, 165, 390-394.
59. Mei, W.; Zhang, J.X.; Xiao, Z. Acute effects of sublingual buprenorphine on brain responses to heroin-related cues in early-abstinent heroin addicts: an uncontrolled trial. Neuroscience, 2010, 170, 808-815.
60. Thompson, P.M.; Hayashi, K.M.; Simon, S.L.; Geaga, J.A.; Hong, M.S.; Sui, Y.; Lee, J.Y.; Toga, A.W.; Ling, W.; London, E.D. Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci, 2004, 24, 6028-6036.
61. Moreno-López, L.; Catena, A.; Fernández-Serrano, M.J.; Delgado- Rico, E.; Stamatakis, E.A.; Pérez-García, M.; Verdejo-García, A. Trait impulsivity and prefrontal gray matter reductions in cocaine dependent individuals. Drug Alcohol Depend, 2012, Mar 3. [Epub ahead of print]
62. Wexler, B.E.; Gottschalk, C.H.; Fulbright, R.K.; Prohovnik, I.; Lacadie, C.M.; Rounsaville, B.J.; Gore, J.C. Functional magnetic resonance imaging of cocaine craving. Am J Psychiatry, 2001, 158, 86-95.
63. Kilts, C.; Schweitzer, J.B.; Quinn, C.K.; Gross, R.E.; Faber, T.L.; Muhammad, F.; Ely, T.D.; Hoffmann, J.M.; Drexler, K.P.G. Neural activity related to drug craving in cocaine addiction. Arch Gen Psychiatry, 2001, 58, 334-341.
64. Volkow, N.D.; Wang, G.J.; Telang, F.; Fowler, J.S.; Logan, J.; Childress, A.R.; Jayne, M.; Ma, Y.; Wong, C. Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine ad- diction. J Neurosci, 2006, 26, 6583-6588.
65. Kufahl, P.R.; Li, Z.; Risinger, R.C.; Rainey, C.J.; Wu, G.; Bloom, A.S.; Li, S.J. Neural responses to acute cocaine administration in the human brain detected by fMRI. Neuroimage, 2005, 28, 904-914.
66. Yücel, M.; Solowij, N.; Respondek, C.; Whittle, S.; Fornito, A.; Pantelis, C.; Lubman, DI. Regional brain abnormalities associated with long-term heavy cannabis use. Arch Gen Psychiatry, 2008, 65, 694-701.
67. Filbey, F.M.; Schacht, J.P.; Myers, U.S.; Chavez, R.S.; Hutchison, K.E. Marijuana craving in the brain. Proc Natl Acad Sci U S A, 2009, 106, 13016-13021.
68. Cousijn, J.; Goudriaan, A.E.; Ridderinkhof, K.R.; van den Brink, W.; Veltman, D.J.; Wiers, R.W. Neural responses associated with cue-reactivity in frequent cannabis users. Addict Biol, 2012, Jan 20. [Epub ahead of print]
69. Denier, N.; Walter, M.; Bendfeldt, K.; Lang, U.; Borgwardt, S. Resting state abnormalities in psychosis compared to acute can- nabinoids and opioids challenges: A systematic review of functional imaging studies. Curr Pharm Des, 2012, Jun 6. [Epub ahead of print]
70. Welch, K.A.; Stanfield, A.C.; McIntosh, A.M.; Whalley, H.C.; Job, D.E.; Moorhead, T.W.; Owens, D.G.; Lawrie, S.M.; Johnstone, E.C. Impact of cannabis use on thalamic volume in people at familial high risk of schizophrenia. Br J Psychiatry, 2011, 199, 386-390.
71. Shenton, M.E., Dickey, C.C.; Frumin, M.; McCarley, R.W. A review of MRI findings in schizophrenia. Schizophr Res, 2001, 49, 1-52.
72. Fusar-Poli, P.; Radua, J.; McGuire, P.; Borgwardt S. Neuro-anatomical Maps of Psychosis Onset: Voxel-wise Meta-Analysis of Antipsychotic-Naive VBM Studies. Schizophr Bull, 2011, Nov 17. [Epub ahead of print]
73. Lieberman, J.; Chakos, M.; Wu, H. Longitudinal study of brain morphology in first episode schizophrenia. Biol Psychiatry, 2001, 49, 487-499.
74. Ho, B.C.; Alicata, D.; Ward, J.; Moser, D.J.; O'Leary, D.S.; Arndt, S.; Andreasen, N.C. Untreated initial psychosis: relation to cognitive deficits and brain morphology in first-episode schizophrenia. Am J Psychiatry, 2003, 160, 142-148.
75. Pantelis, C.; Velakoulis, D.; McGorry, P.D.; Wood, S.J.; Suckling, J.; Phillips, L.J.; Yung, A.R.; Bullmore, E.T.; Brewer, W.; Soulsby, B.; Desmond, P.; McGuire, P.K. Neuroanatomical abnormalities before and after onset of psychosis: A cross-sectional and longitudinal MRI comparison. Lancet, 2003, 361, 281-288.
76. Koo, M.S.; Dickey, C.C.; Park, H.J.; Kubicki, M.; Ji, N.Y.; Bouix, S.; Pohl, K.M.; Levitt, J.J.; Nakamura, M.; Shenton, M.E.; McCarley, R.W. Smaller neocortical gray matter and larger sulcal cere-brospinal fluid volumes in neuroleptic-naive women with schizotypal personality disorder. Arch Gen Psychiatry, 2006, 63, 1090-1100.
77. Stern AJ, Savostyanova AA, Goldman A, Barnett AS, van der Veen JW, Callicott JH, Mattay VS, Weinberger DR, Marenco S. Impact of the brain-derived neurotrophic factor Val66Met poly- morphism on levels of hippocampal N-acetyl-aspartate assessed by magnetic resonance spectroscopic imaging at 3 Tesla. Biol Psy- chiatry, 2008, 64: 856-862.
78. Baare, W.F., van Oel, C.J.; Hulshoff Pol, H.E.; Schnack, H.G.; Durston, S.; Sitskoorn, M.M.; Kahn, R.S. Volumes of brain structures in twins discordant for schizophrenia. Arch Gen Psychiatry, 2001, 58, 33-40.
79. Ettinger, U.; Schmechtig, A.; Toulopoulou, T.; Borg, C.; Orrells, C.; Owens, S.; Matsumoto, K.; van Haren, N.E.; Hall, M.H.; Kumari, V.; McGuire, P.K.; Murray, R.M.; Picchioni, M. Prefrontal and striatal volumes in monozygotic twins concordant and discordant for schizophrenia. Schizophr Bull, 2012, 38, 192-203.
80. McGuire, P.; Howes, O.D.; Stone, J.; Fusar-Poli, P. Functional neuroimaging in schizophrenia: diagnosis and drug discovery. Trends Pharmacol Sci, 2008, 29, 91-98.
81. Achim, A.M.; Lepage, M. Episodic memory-related activation in schizophrenia: meta-analysis. Br J Psychiatry, 2005, 187, 500-509.
82. Ranganath, C.; Minzenberg, M.J.; Ragland, J.D. The cognitive neuroscience of memory function and dysfunction in schizophrenia. Biol Psychiatry, 2008, 64, 18-25.
83. Minzenberg, M.J., Laird, A.R.; Thelen, S.; Carter, C.S.; Glahn, D.C. Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. Arch Gen Psychiatry, 2009, 66, 811-822.
84. Soyka, M.; Koch, W.; Moller, H.J.; Ruther, T.; Tatsch, K. Hyper- metabolic pattern in frontal cortex and other brain regions in unmedicated schizophrenia patients. Results from a FDG-PET study. Eur Arch Psychiatry Clin Neurosci, 2005, 255, 308-312.
85. Semkovska, M.; Bedard, M.A.; Stip, E. Hypofrontality and negative symptoms in schizophrenia: synthesis of anatomic and neuro- psychological knowledge and ecological perspectives. Encephale, 2001, 27, 405-415.
86. Tamminga, C.A.; Stan, A.D.; Wagner, A.D. The hippocampal formation in schizophrenia. Am J Psychiatry, 2010, 167, 1178-1193.
87. Van der Meer, L.; Costafreda, S.; Aleman, A.; David, A.S. Self-reflection and the brain: a theoretical review and meta-analysis of neuroimaging studies with implications for schizophrenia. Neurosci Biobehav Rev, 2010, 34, 935-946.
88. Fisher, M.; McCoy, K.; Poole, J.H.; Vinogradov, S. Self and other in schizophrenia: a cognitive neuroscience perspective. Am J Psychiatry, 2008, 165, 1465-1472.
89. Seal, M.L.; Aleman, A.; McGuire, P.K. Compelling imagery, unanticipated speech and deceptive memory: neurocognitive models of auditory verbal hallucinations in schizophrenia. Cogn Neu- ropsychiatry, 2004, 9, 43-72.
90. Cahn, W.; Hulshoff Pol, H.E.; Lems, E.B.; van Haren, N.E.; Schnack, H.G.; van der Linden, J.A.; Schothorst P.F.; van Engeland, H.; Kahn, R.S. Brain volume changes in first-episode schizophrenia: a 1-year follow-up study. Arch Gen Psychiatry, 2002,59, 1002-1010.
91. Cahn, W.; Rais, M.; Stigter, F.P.; van Haren, N.E.; Caspers, E.; Hulshoff Pol, H.E.; Xu, Z.; Schnack, H.G.; Kahn, R.S. Psychosis and brain volume changes during the first five years of schizo- phrenia. Eur Neuropsychopharmacol, 2009, 19, 147-151.
92. Job, D.E.; Whalley, H.C.; Johnstone, E.C.; Lawrie, S.M. Grey matter changes over time in high risk subjects developing schizophrenia. Neuroimage, 2005, 25, 1023-1030.
93. Borgwardt, S.J.; McGuire, P.K.; Aston, J.; Gschwandtner, U.; Pflüger, M.O.; Stieglitz, R.D.; Radue, E.W.; Riecher-Rössler, A. Reductions in frontal, temporal and parietal volume associated with the onset of psychosis. Schizophr Res 2008, 106, 108-114.
94. Smieskova, R.; Fusar-Poli, P.; Allen, P.; Bendfeldt, K.; Stieglitz, R.D.; Drewe, J.; Radue, E.W.; McGuire, P.K.; Riecher-Rössler, A.; Borgwardt, S.J. The effects of antipsychotics on the brain: What have we learnt from structural neuroimaging of schizophrenia?-A systematic review. Curr Pharm Des, 2009, 15, 2535-2549.
95. Cahn, W.; Hulshoff Pol, H.E.; Caspers, E.; van Haren, N.E.; Schnack, H.G.; Kahn, R.S. Cannabis and brain morphology in recent-onset schizophrenia. Schizophr Res, 2004, 67, 305-307.
96. Wobrock, T.; Sittinger, H.; Behrendt, B.; D'Amelio, R.; Falkai, P. Comorbid substance abuse and brain morphology in recent-onset psychosis. Eur Arch Psychiatry Clin Neurosci, 2009, 259, 28-36.
97. Sevy, S.; Robinson, D.G.; Holloway, S.; Alvir, J.M.; Woerner, M.G.; Bilder, R., Goldman, R.; Lieberman, J.; Kane, J. Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. Acta Psychiatr Scand, 2001, 104, 367-374.
98. Schiffer, B.; Müller, B.W.; Scherbaum, N.; Forsting, M.; Wiltfang, J., Leygraf, N.; Gizewski, E.R. Impulsivity-related brain volume deficits in schizophrenia-addiction comorbidity. Brain, 2010, 133, 3093-3103.
99. Rapp, C.; Bugra, H.; Riecher-Rössler, A.; Borgwardt, S. Curr Pharm Des, 2012, Jun 7. [Epub ahead of print]
100. Rais, M.; Cahn, W.; Van Haren, N.; Schnack, H.; Caspers, E.; Hulshoff Pol, H.; Kahn, R. Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. Am J Psychiatry, 2008, 165, 490-496.
101. Mathalon, D.H.; Pfefferbaum, A.; Lim, K.O.; Rosenbloom, M.J.; Sullivan, E.V. Compounded brain volume deficits in schizophre-nia-alcoholism comorbidity. Arch Gen Psychiatry, 2003, 60, 245-252.
102. Smith, M.J.; Wang, L.; Cronenwett, W.; Goldman, M.B.; Mamah, D.; Barch, D.M.; Csernansky, J.G. Alcohol use disorders contribute to hippocampal and subcortical shape differences in schizophrenia. Schizophr Res, 2011, 131, 174-183.
103. Spanagel, R.; Heilig, M. Addiction and its brain science. Addic- tion, 2005, 100, 1813-1822.
104. Fazel, S.; Langstroem, N.; Hjern, A.; Grann, M.; Lichtenstein, P. Schizophrenia, substance abuse, and violent crime. JAMA, 2009, 301, 2016-2023.
105. Mancini-Marïe, A.; Potvin, S.; Fahim, C.; Beauregard, M.; Mensour, B.; Stip, E. Neural correlates of the affect regulation model in schizophrenia patients with substance use history: a functional magnetic resonance imaging study. J Clin Psychiatry, 2006, 67, 342-350.
106. Potvin, S.; Mancini-Marie, A.; Mensour, B.; Stip, E. Processing if social emotion in patients with schizophrenia and substance use disorder: An fMRI study. Soc Neurosci, 2007, 2, 106-116.
107. Joyal, C.C.; Putkonen, A.; Mancini-Marïe, A.; Hodgins, S.; Ko- nonen, M.; Boulay, L.; Pihlajamaki, M.; Soininen, H.; Stip, E.; Ti- ihonen, J.; Aronen, H.J. Violent persons with schizophrenia and comorbid disorders: a functional magnetic resonance imaging study. Schizophr Res, 2007, 91, 97-102.